Karl Nägler

Atlas Venture GmbH was the Munich office of the independent and partner-owned venture capital investment group Atlas Venture Inc., headquartered in Boston with additional offices in London and Paris, plus an administrative office in Amsterdam. The group originated in 1980 and focuses on high-technology financing, aiming for a transatlantic operations model. The Munich office was established in the late 1990s. The group manages a range of venture capital funds. Atlas Venture GmbH was liquidated in 2009.

Shogoo Pharmaceuticals KK provides novel pharmaceutical products. It also licenses, develops, imports, exports, markets, and distributes pharmaceutical products. It provides medicines mainly for high unmet diseases. Shogoo Pharmaceuticals was founded in 2005 and is located in Tokyo, Japan.

Horizon Therapeutics Schweiz GmbH is a biopharmaceutical company that develops and commercializes medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company was originally founded in 2004 as a spin-out of Merck KGaA and is headquartered in Reinach, Switzerland.

Ventech SA is part of the venture capital arm and a wholly-owned subsidiary of Natixis Private Equity (NPE), which in turn is a subsidiary of Paris-based Natixis SA (XP: KN). Ventech was established in 1998 and is located in Paris. The firm specializes in technology venture capital investing. Ventech manages venture capital funds for a clientele of European institutional investors, with NPE as their sponsor. The firm relies on international strategic alliances with seeding funds and venture capital firms in Germany, Switzerland, Israel, Japan and the US.

Covagen AG engages in the research in as well as development, production, and distribution of pharmaceutical and diagnostic products and technologies. The company was founded by Julian Bertschinger and Dragan Grabulovski in 2007 and is headquartered in Zug, Switzerland.

Biom'Up SA engages in the development of hemostatic product composed of patent-protected biopolymers. Its products include Hemoblast Bellows and Hemosnow. The company was founded by Patricia Forest, Sylvain Picot and Christian Gagnieu on February 21, 2005 and is headquartered in Lyon, France.

Prosonix Ltd. engages in the provision of inhaled respiratory medicines. The company was founded by Andre James Bush and David Hipkiss in 2006 and is headquartered in Oxford, the United Kingdom.

Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium.